The Effect of Vitamin D Supplementation on Insulin Resistance in Patients with Nonalcoholic Fatty Liver

Document Type : Original Article (s)

Authors

1 Food Security Research Center AND Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

2 PhD Candidate, Food Security Research Center AND Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 Assistant Professor, Food Security Research Center AND Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Non-alcoholic fatty liver disease is the most common chronic liver disease in worldwide. Prevalence of the disease is about 35 percent in Iran. Metabolic disorders were seen in patients with nonalcoholic fatty liver. In several studies, vitamin D supplementation led to ameliorate glycemic indicator. The purpose of this study was to investigate the effect of vitamin D supplementation on glycemic indices in patients with nonalcoholic fatty liver.Methods: In this randomized parallel clinical trial, 60 patients with non-alcoholic fatty liver disease participated in the intervention and placebo groups. For 10 weeks, the intervention and placebo groups received  50,000 IU Pearle vitamin D or placebo, respectively. Glycemic indices were measured at the beginning and end of the study. Nonalcoholic fatty liver was diagnosed via ultrasound. Data were analyzed using ANCOVA and regression tests in SPSS software.Findings: At the end of the study, in intervention group, compared with the placebo group, serum vitamin D levels were significantly increased and insulin resistance and fasting blood glucose levels were significantly decreased (P < 0.05). But, vitamin D supplementation had not significant effect on other variables.Conclusion: Vitamin D supplementation reduced insulin resistance in patients with nonalcoholic fatty liver. But, more researches must be conducted with large sample sizes and strong designs to confirm these findings.

Keywords

References

  1. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118(4): 1388-93.
  2. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009; 50(4): 1282-93.
  3. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42(1): 132-8.
  4. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 2002; 97(9): 2460-2.
  5. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008; 118(3): 277-83.
  6. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55(7): 434-8.
  7. Kleiner DE, Brunt EM, Van Natt M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41(6): 1313-21.
  8. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42(3): 641-9.
  9. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143(4): 500-5.
  10. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006; 92(1): 39-48.
  11. Alvarez JA, Ashraf A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010; 2010: 351385.
  12. Su Y, Ye L. Can vitamin D intake assist in improving the outcome of endodontic treatment for diabetic patients? Med Hypotheses 2010; 74(4): 673-5.
  13. Foss YJ. Vitamin D deficiency is the cause of common obesity. Med Hypotheses 2009; 72(3): 314-21.
  14. Zhang Z, Zhang Z. Comment on "Vitamin D deficiency is the cause of common obesity". Med Hypotheses 2009; 73(1): 123.
  15. Mattila C, Knekt P, Mannisto S, Rissanen H, Laaksonen MA, Montonen J, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 2007; 30(10): 2569-70.
  16. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 2008; 10(3): 185-97.
  17. Pietschmann P, Schernthaner G, Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia 1988; 31(12): 892-5.
  18. Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 2001; 24(8): 1496.
  19. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de IR, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90(6): 3498-504.
  20. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107(5): 450-5.
  21. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87(7): 3023-8.
  22. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338(13): 867-72.
  23. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007; 30(4): 980-6.
  24. Lind L, Pollare T, Hvarfner A, Lithell H, Sorensen OH, Ljunghall S. Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 1989; 11(3): 141-7.
  25. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010; 53(10): 2112-9.
  26. Ryu OH, Lee S, Yu J, Choi MG, Yoo HJ, Mantero F. A prospective randomized controlled trial of the effects of vitamin D supplementation on long-term glycemic control in type 2 diabetes mellitus of Korea. Endocr J 2014; 61(2): 167-76.
  27. Maestro B, Davila N, Carranza MC, Calle C. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003; 84(2-3): 223-30.
  28. Simpson RU, Thomas GA, Arnold AJ. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem 1985; 260(15): 8882-91.
  29. Cheng Q, Li YC, Boucher BJ, Leung PS. A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia 2011; 54(8): 2077-81.
  30. Ojuka EO. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc 2004; 63(2): 275-8.
  31. Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 2005; 349(2): 248-60.
  32. Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol 2007; 103(3-5): 558-62.
  33. Foroughi M, Maghsoudi Z, Ghiasvand R, Iraj B, Askari G. Effect of Vitamin D Supplementation on C-reactive Protein in Patients with Nonalcoholic Fatty Liver. Int J Prev Med 2014; 5(8): 969-75.
  34. Foroughi M, Maghsoudi Z, Khayyatzadeh S, Ghiasvand R, Askari Gh, Iraj B. Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. ABR; 2014: 717(13). [In Press].
  35. Foroughi M, Maghsoudi Z, Ghiasvand R, Esmaillzadeh A, Iraj B, Askari Gh, Adibi P. The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver (NAFLD). Iran J Nurs Midwifery Res; 2014. [In Press].
Journal of Isfahan Medical School
Volume 33, Issue 342 - Serial Number 342
May and June 2015
Pages 1076-1085

Files

History

  • Receive Date: 31 December 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics